Drug EfficacyCasdatifan monotherapy has demonstrated a longer median progression-free survival of approximately 12.2 months compared to belzutifan, suggesting a potential for longer median PFS with cas + cabo.
Early Treatment BenefitsThe LITESPARK-022 trial shows positive potential for HIF2α inhibitors to be used in early treatment of RCC, indicating benefit across the treatment paradigm.
Pipeline ExpansionThe unveiling of five early-stage programs in autoimmune and inflammatory diseases indicates a strong pipeline and future growth potential.